Literature DB >> 20656221

Ultrasound-accelerated thrombolysis in arterial and venous peripheral occlusions: fibrinogen level effects.

Rodney D Raabe1.   

Abstract

PURPOSE: This study retrospectively assesses whether significantly accelerating thrombolysis with ultrasound affects fibrinogen levels in the treatment of peripheral arterial occlusions.
MATERIALS AND METHODS: Between December 2005 and August 2007, 38 limbs in 38 patients (17 women; mean age, 60.5 +/- 19.7 years; age range, 17-94 years) were treated with ultrasound-accelerated thrombolysis for peripheral arterial occlusion (PAO) and deep vein thrombosis (DVT), with serum fibrinogen levels measured at baseline and every 24 hours. All occlusions were treated with alteplase (0.5-1.0 mg/h).
RESULTS: Complete or partial lysis was achieved in 92.1% of patients. All patients received thrombolytic therapy with mean infusion time of 42.3 hours (range, 20-96 hours). As part of standard clinical practice, patients were not assessed angiographically overnight. Mean total alteplase dose was 40.6 mg (range, 18-96 mg). Across all patients, the fibrinogen level at the end of infusion decreased by an average of 18.5% from baseline, and no patient exhibited a fibrinogen level < 100 mg/dL during treatment. Fibrinogen depletion was more pronounced among patients with venous occlusions (26.4% from baseline) than those with arterial occlusions (15.8% from baseline). No major hemorrhagic complications occurred. One patient (2.6%) experienced a minor bleeding event at the access site, and use of thrombolytics was discontinued; and one patient with a chronic arterial occlusion and underlying coronary disease who did not respond to thrombolytic therapy, experienced an acute myocardial infarction. Of documented 30-day clinical outcomes in 20 patients, 80.0% remained patent at 30 days.
CONCLUSIONS: Ultrasound-accelerated thrombolysis for the treatment of PAO and DVT is associated with a very low complication rate and nominal fibrinogen depletion. Copyright (c) 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656221     DOI: 10.1016/j.jvir.2010.03.020

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

1.  SonoKnife: feasibility of a line-focused ultrasound device for thermal ablation therapy.

Authors:  Duo Chen; Rongmin Xia; Xin Chen; Gal Shafirstein; Peter M Corry; Robert J Griffin; Jose A Penagaricano; Ozlem E Tulunay-Ugur; Eduardo G Moros
Journal:  Med Phys       Date:  2011-07       Impact factor: 4.071

Review 2.  Limb ischemia: cardiovascular diagnosis and management from head to toe.

Authors:  Sreekanth Vemulapalli; Manesh R Patel; W Schuyler Jones
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

3.  Successful microbubble sonothrombolysis without tissue-type plasminogen activator in a rabbit model of acute ischemic stroke.

Authors:  William C Culp; Rene Flores; Aliza T Brown; John D Lowery; Paula K Roberson; Leah J Hennings; Sean D Woods; Jeff H Hatton; Benjamin C Culp; Robert D Skinner; Michael J Borrelli
Journal:  Stroke       Date:  2011-06-23       Impact factor: 7.914

Review 4.  A systematic review of ultrasound-accelerated catheter-directed thrombolysis in the treatment of deep vein thrombosis.

Authors:  Yadong Shi; Wanyin Shi; Liang Chen; Jianping Gu
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

Review 5.  Acute Limb Ischemia Therapies: When and How to Treat Endovascularly.

Authors:  Anthony N Hage; Joseph L McDevitt; Jeffrey Forris Beecham Chick; Venu Vadlamudi
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

6.  Efficacy of ultrasound-accelerated versus traditional catheter-directed thrombolysis in treatment of lower extremity deep venous thrombosis: A protocol for systematic review and meta-analysis.

Authors:  Shan Ma; Zhizhen Zhao; Zhijun Song; Li Wang
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.